Thousands of end stage renal disease experts turn to Renal Therapies Group for pharmaceuticals and the most prescribed technologies in the industry.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Success! The link has been copied to your clipboard.
In July 2018, Fresenius Medical Care announced a global partnership with Humacyte, to make their human acellular vessel, HUMACYL®, available to more hemodialysis patients worldwide upon approval by appropriate regulatory authorities. In this video, Dr. Frank Maddux takes us into their lab to explain how this bioengineered blood vessel will potentially improve vascular access and health outcomes for our patients in need of dialysis. For more information about this partnership, please also read our Q&A with Carrie Cox, Humacyte’s Executive Chairman and former Chief Executive Officer.